Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics-Reference-Cited by-同舟云学术

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics

Published:2021 Issue:3 Volume:12 Page:370-379
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Oerlemans Rick¹²³,Ruiz-Moreno Angel Jonathan¹²³⁴⁵^ORCID,Cong Yingying⁶²⁷³,Dinesh Kumar Nilima⁶²⁷³⁸,Velasco-Velazquez Marco A.⁴⁵⁹¹⁰¹¹,Neochoritis Constantinos G.¹²¹³³^ORCID,Smith Jolanda⁸²⁷¹⁴³,Reggiori Fulvio⁶²⁷³,Groves Matthew R.¹²³,Dömling Alexander¹²³¹²¹³^ORCID

Affiliation:

1. Department of Drug Design

2. University of Groningen

3. The Netherlands

4. Departamento de Farmacología y Unidad Periférica de Investigación en Biomedicina Traslacional

5. Facultad de Medicina

6. Department of Biomedical Sciences of Cells and Systems

7. University Medical Center Groningen

8. Department of Medical Microbiology and Infection Prevention

9. Universidad Nacional Autónoma de México (UNAM)

10. Ciudad de México

11. Mexico

12. Telesis Pharma

13. Groningen

14. Groningen 9700 RB

Abstract

α-Ketoamide HCV protease inhibitors covalently bind to SARS-CoV-2 3CLpro. Boceprevir is a particular promising repurposed drug as it potently inhibits cellular viral proliferation.

Funder

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Horizon 2020 Framework Programme

Universidad Nacional Autónoma de México

Consejo Nacional de Ciencia y Tecnología

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/MD/D0MD00367K

Reference41 articles.